Metronidazole 0.2% And Dextrose 5% w/v Injection
| Product/Composition:- | Metronidazole 0.2% And Dextrose 5% w/v Injection |
|---|---|
| Strength:- | 250ml / 500ml / 1000ml |
| Form:- | Injection |
| Production Capacity | 1 Million Injection/Month |
Description
Metronidazole is a nitroimidazole anti-infective medication used mainly in the treatment of infections caused by susceptible organisms, particularly anaerobic bacteria and protozoa. It is marketed by Pfizer under the trade name Flagyl in the US, by Sanofi-Aventis globally under the same tradename, Flagyl, and by various generic manufacturers. Metronidazole is also used as a gel preparation in the treatment of the dermatological conditions such as rosacea (Rozex and MetroGel by Galderma) and ungating tumours (Anabact, Cambridge Healthcare Supplies).
Metronidazole is converted to reduction products that interact with DNA to cause destruction of helical DNA structure and strand leading to a protein synthesis inhibition and cell death in susceptible organisms. It is effective against a wide range of organisms including E. histolytica, T. vaginalis, Giardia, anaerobes e.g. Bacterioides sp, Fusobacterium sp, Clostridium sp, Peptococcus sp and Peptostreptococcus sp, and moderately active against Gardnerella sp and Campylobacter sp.